40 studies found for:    Open Studies | "intraocular melanoma"
Show Display Options
Rank Status Study
21 Unknown  Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
Conditions: Bladder Cancer;   Brain and Central Nervous System Tumors;   Esophageal Cancer;   Intraocular Melanoma;   Kidney Cancer;   Lymphoma;   Melanoma (Skin);   Pancreatic Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration
22 Recruiting Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Ocular Melanoma With Extraocular Extension;   Recurrent Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Vorinostat
23 Unknown  Treatment Of Radiation Retinopathy Trial
Condition: Uveal Melanoma
Interventions: Drug: ranibizumab;   Drug: triamcinolone acetonide;   Other: sham
24 Recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Conditions: Carcinoma of Unknown Primary Origin;   Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Mucosal Melanoma;   Ocular Melanoma With Extraocular Extension;   Small Size Posterior Uveal Melanoma;   Stage IIB Skin Melanoma;   Stage IIB Uveal Melanoma;   Stage IIC Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Skin Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Skin Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Other: Laboratory Biomarker Analysis;   Biological: Neoantigen-based Melanoma-Poly-ICLC Vaccine;   Other: Pharmacological Study;   Biological: Recombinant Flt3 Ligand
25 Recruiting Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
Condition: Uveal Melanoma
Interventions: Drug: AEB071;   Drug: BYL719
26 Recruiting INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Conditions: Mucosal Melanoma;   Recurrent Melanoma;   Recurrent Uveal Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Skin Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Skin Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: IDO1 Inhibitor INCB024360;   Biological: MELITAC 12.1 Peptide Vaccine;   Other: Laboratory Biomarker Analysis
27 Recruiting Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Conditions: Recurrent Uveal Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Dacarbazine;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide
28 Recruiting Study Of Surgical Radiation Shielding With Vitrectomy And Silicone Oil Tamponade For The Protection Of Radiation Induced Ocular Injury
Condition: Choroidal Melanoma
Intervention: Other: 1000CsK Silicon Oil Tamponade
29 Unknown  Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone
Conditions: Ocular Melanoma;   Choroidal Melanoma;   Uveal Melanoma
30 Recruiting Clinical and Histopathologic Characteristics of BAP1 Mutations
Conditions: Malignant Pleural Mesothelioma (MPM);   Choroidal Nevus;   Primary Uveal Melanoma (UM);   Metastatic Uveal Melanoma (UM);   Renal Cell Carcinoma;   Cholangiocarcinoma
Intervention: Other: tumor specimens
31 Recruiting Cytogenetic Study of Ocular Melanoma
Condition: Choroidal Melanoma
32 Recruiting Vascular Response to Brachytherapy Using Functional OCT
Condition: Uveal Melanoma
33 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Conditions: Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma
Interventions: Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Young TIL
34 Recruiting Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Conditions: Pleural Mesothelioma Malignant Advanced;   Peritoneal Mesothelioma Malignant Advanced;   Non-squamous Non-small Cell Lung Carcinoma Stage IIIB/IV (NSCLC);   Metastatic Uveal Melanoma;   Hepatocellular Carcinoma (HCC);   Glioma
Intervention: Drug: ADI-PEG 20
35 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Conditions: Mucosal Melanoma;   Stage IV Skin Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: Bevacizumab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study
36 Recruiting Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Condition: Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Intervention: Drug: ADI-PEG 20
37 Unknown  Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
Condition: Ocular Melanoma
38 Unknown  Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma
Conditions: Melanoma;   Radiotherapy;   Metastatic Disease
Intervention: Procedure: Treatment of metastatic disease
39 Recruiting The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases
Conditions: Melanoma;   Uveal Neoplasms
Intervention: Procedure: IHP
40 Recruiting Definity for Ultrasound of Intraocular Tumors
Condition: Ocular Melanoma
Intervention: Device: Microbubble contrast agent

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page   
Indicates status has not been verified in more than two years